Effect of Efpeglenatide on Cardiovascular Outcomes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4076 participants.

Also called NCT03496298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,076 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03496298
  • EudraCT 2017-002954-35
Other papers using this trial's data
  • Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes The New England journal of medicine, 2021-09-02 DOI, PubMed 34215025
  • Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial Circulation, 2022-02-22 DOI, PubMed 34775781 PubMed links an erratum for this paper. Erratum: PMID 37276255
  • Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial Circulation, 2023-03-28 DOI, PubMed 36802715

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Bulgaria, Canada, Chile, Denmark, Estonia, Finland, Germany, Hungary, India, Italy, Latvia, Lithuania, Mexico, Norway, Peru, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, Ukraine (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03496298. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-27 (actual); primary completion 2020-12-10 (actual). Results posted on 2021-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Efpeglenatide on Cardiovascular Outcomes
Acronym
AMPLITUDE-O
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Efpeglenatide (SAR439977)
Intervention (Drug)
Placebo
Lead sponsor
Sanofi (class: industry)
Collaborator
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct03496298
Content hash
163607ba9df575dabd5f362763a82e5aae9a709cb9e4da48f1e3c5ad7754fc0f